Investor sues Dendreon over Provenge sales info; Bristol-Myers launches offer for Amylin;

 @FiercePharma: Can a new CEO turn Savient around? Regrouping after weak Krystexxa sales, Savient to lay off 35% of workforce. News | Follow @FiercePharma

> Dendreon ($DNDN) was sued by an investor claiming that the company withheld information about sales of its cancer treatment Provenge that, when released, triggered a big drop in share price. Report

> Bristol-Myers Squibb ($BMY) officially launched its $31-per-share tender offer to buy diabetes drug specialist Amylin Pharmaceuticals ($AMLN), part of a two-stage deal that also expands a partnerhsip with AstraZeneca ($AZN). Article

> Eisai said its breast cancer drug Halaven failed a study in women with locally advanced or metastatic breast cancer who were previously treated with certain drugs. Report

> Contract manufacturer Siegfried plans to build a new active pharmaceutical ingredients plant in China. News

> FDA warned drugmakers to keep an eye on their supply chain for glycerin made from a plant used in biodiesel. Report

> Australian regulators declined to pull the Sanofi ($SNY) sleep drug Stilnox and its generics from the market despite worries about side effects, especially sleep walking and sleep driving. Report

> Sinclair IS Pharma expects fiscal year revenue to leap 56% on strong sales of its key skin product Kelo-cote. Story

Biotech News

 @FierceBiotech: Analysis: Top 20 ‪#biotech‬ licensing deals in H1 2012 - a buyer's market dominates the deal scene. Special Report | Follow @FierceBiotech

 @JohnCFierce: J&J licensing a portfolio of diabetes products from Evotec. $8M up, up to $300M down per product in milestones. Release | Follow @JohnCFierce

 @RyanMFierce: Ipsen (France) and Inspiration Biopharma (Cambridge, MA) halt late-stage hemophilia drug trials, program in question. Story | Follow @RyanMFierce

> Ipsen shares slide after FDA orders hold on PhIII hemophilia drug trials. Article

> Struggling Chelsea jettisons staffers, plots survival strategy. Story

> Regulatory setback raises fresh questions about Sanofi R&D comeback. News

Medical Device News

@FierceMedDev: Devicemaker Avinger pulled in $33M in fundraising to develop catheters. Item | Follow @FierceMedDev

@MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

@DamianFierce: Abbott nabbed a CE mark for a new diabetes diagnostic the company says bests glucose monitors. Article | Follow @DamianFierce

> Obama signs FDA user fee extension. Story

> FDA sticks Class I label on Maquet's anesthesia device recall. News

> Avinger snags $33M to develop PAD catheters. Item

> St. Jude smacked with breach-of-contract suit over valve tech royalty payments. Article

Pharma Manufacturing News

 @EricPFierce: FDA‬ warning letters , 483 reports can suggest a tipping point has been reached by a drug company. How about yours? Special Report | Follow @EricPFierce

> Ireland campus becomes Eli Lilly's launch pad. Story

> Abemarle again expands Michigan API plant. News

> AEI suggests booting WHO drugmakers that don't meet the grade. More

Biotech Research News

> Key molecule spotted as possible lung cancer weapon. Story

> Mouse model connects specific gene to liver cancer advance. Item

> Acadia's Parkinson's drug shows promise in treating Alzheimer's psychosis. More

> Nanomedicine busts deadly clots in promising mouse study. Article

And Finally... Finally, a video game that really is good for the brain. Report